0347: Leucine, a potent inhibitor of cardiac glucose uptake  by Renguet, Edith et al.
© Elsevier Masson SAS. All rights reserved.
 
Archives of Cardiovascular Diseases Supplements (2014) 6, 13-14 13
Topic 6 – Diabetes, lipids, metabolism – B
0260
Imidazoline I1 receptor ligands activate hepatic adiponectin pathways
and thus improve insulin sensitivity
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Metabolic syndrome is defined as a cluster of cardiovascular and metabolic
disorders. Previous studies in rat models of metabolic syndrome have demon-
strated that ligands selective for I1 imidazoline receptor (LNPs) increase
insulin sensitivity through central sympathoinhibition and an additional
peripheral effect attributable to adiponectin, a major insulin-sensitizer adipo-
kine. The objective of this study was to explore possible direct actions on
hepatocytes, one of the target cells of insulin and adiponectin.
Experiments were carried out in HepG2 cells, a cell line of hepatocytes. In
order to evaluate the effect of LNPs on insulin sensitivity, the activation (i.e.
phosphorylation) of a key actor of insulin pathways, AKT, was evaluated by
measuring the ratio pAKT/AKT by Western Blot. Similarly, the effect of
LNPs on adiponectin signaling was evaluated by measuring the rate of phos-
phorylation of the central kinase involved in adiponectin pathways, AMPK, by
Western Blot. Insulin (10 μM) induced the phosphorylation of AKT (pAKT/
AKT=0.49±0.16) compared to control without insulin (pAKT/AKT=0.11±0.03;
p≤0.05) whereas LNPs (1μM) alone did not. Interestingly, pretreatment by
LNPs (1 μM) during 60 min could potentiate the insulin-induced activation of
AKT: LNP509: pAKT/AKT=1.13±0.18 (p≤0.05 vs insulin alone); LNP599:
pAKT/AKT=1.23±0.16 (p=0.0545 vs insulin alone).
Concerning adiponectin signaling pathways, LNPs alone (from 10-9 M to
10-4 M) increased AMPK phosphorylation in a concentration- and time-depen-
dent manner. The maximal effect was obtained after 10 min exposure of LNPs
10 μM (untreated cells: pAMPK/AMPK=0.18±0.04; LNP 509 pAMPK/
AMPK=0.38±0.05 p≤0.05; LNP599 pAMPK/AMPK=0.46±0.17). These data
suggest that LNPs on hepatic cells activate adiponectin pathways and poten-
tiate insulin action. These two direct effects on insulin sensitive cells could
account for the ameliorated insulin sensitivity observed in vivo.
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Sodium-glucose cotransporters (SGLT) in the heart. Contribution of
SGLT-type of transport in hyperglycemia-induced signaling pathway
in adult cardiomyocytes
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Background: Exposure to hyperglycemic conditions increases reactive
oxygen species (ROS) production in adult cardiomyocytes, inducing glucotox-
icity. This is due to an NADPH oxidase activation and more particularly the
NOX2 isoform. Our group has demonstrated that hyperglycemia-induced toxic
effect does not required glucose metabolism but results from glucose transport
through a SGLT type of transport. SGLT acts as glucose sensor. Seven SGLT
isoforms have been described (SGLT1 to 6 and SMIT1) but their expression
in the heart remains to be elucidated. The aim of this work is to study SGLT
isoforms expression in the heart and identify the isoform responsible for glu-
cotoxicity.
Methods: SGLT isoforms expression has been performed in heart extracts
(from rats, mice and humans) and in isolated cardiomyocytes (from rats and
mice) using PCR and westernblotting. The study of the contribution of each
isoforms to glucotoxicity is based on the substrates specifity of all these SGLT
isoforms.
Results: SGLT1, SGLT3 and SMIT1 are expressed in the heart and in car-
diomyocytes from rats and mice as well as in human heart. In human heart,
SGLT3 expression is marginal. SGLT4 is only expressed in rat heart. In pres-
ence of 5 mM glucose, rat cardiomyocytes exposure to high concentration of
galactose (16 mM, transported through SGLT1) does not activate NOX2. By
contrast, myo-inositol (16 mM, transported through SMIT1) completly repro-
duces hyperglycemic effects. Indeed, it favors p47phox translocation inducing
NOX2 activation and stimulates ROS production. This ROS production is
blocked by a NOX2 specific inhibitor (gp91dstat). Similar observation was
perfomed in mice cardiomyocytes.
Conclusion: SGLT1 and SMIT1 are expressed in rats, mice and human
cardiomyocytes. Increased transport through SMIT1 activates NOX2.
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Background: It was demonstrated that branched-chain amino acids like
leucine induce insulin resistance in muscle and adipose tissues. The mecha-
nism proposed to explain leucine action involves mTOR/p70S6K signaling.
This pathway can be activated by leucine and is implicated in the stimulation
of an insulin negative feedback loop. Knowing that insulin-resistance partici-
pates in diabetic cardiomyopathy, we were interested in studying leucine
effect in cardiomyocytes.
Methods: Primary cultured adult rat cardiomyocytes were pretreated with
different concentrations of leucine (from 1 to 10 mM) during different periods
of time (up to 20h) before being exposed to insulin (3x10-9 M, 30 min).
Results: In absence of leucine, insulin induced a 6-fold increase in glucose
uptake (0.31+/-0.04 vs. 0.05+/-0.01 μmoles/mg.h). This correlated with the
increase in phosphorylation state of PKB and AS160, both known to regulate
glucose transport downstream of insulin. Pre-incubation with leucine for 1 h
stimulated mTOR/p70S6K pathway resulting in the inhibiting phosphorylation
of IRS-1 located in the proximal insulin signaling pathway. This is accompanied
by a significant decrease in PKB and AS160 phosphorylation but, surprisingly,
insulin-stimulated glucose uptake was preserved (0.31+/–0.05 μmoles/mg.h). On
the other hand, a longer incubation (14h) with leucine induced a drastic decrease
in glucose transport (0.056+/–0.01 μmoles/mg.h). The mTOR/p70S6K inhibitor
rapamycin did not prevent this inhibition. Moreover, the non-metabolized leu-
cine analog BCH was able to stimulate mTOR/p70S6K pathway but had no
effect on the insulin-mediated stimulation of glucose uptake. By contrast, inter-
mediates of leucine catabolism, alpha-ketoisocaproate, acetoacetate and beta-
hydroxybutyrate, inhibited glucose uptake similarly to leucine.
Conclusion: Leucine catabolism reduces insulin-dependent glucose trans-
port independently of insulin signaling.
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Elevated plasma PCSK9 is equally detrimental for non-familial
hypercholesterolemic (non-FH) and heterozygous FH patients, irres-
pective of their LDL receptor defects
Gilles Lambert
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Objectives: Do elevated PCSK9 levels constitute an even greater risk for
people who already have reduced LDL receptor (LDLR) levels, such as het-
erozygous familial hypercholesterolemic (HeFH) patients?
Methods: Circulating PCSK9 was measured by ELISA in non-treated HeFH
patients carrying either a D206E (n=237), V408M (n=117), or D154N (n=38)
LDLR missense mutation and in normolipidemic controls (n=152). Skin fibro-
blasts and lymphocytes were isolated from a subset of patients and grown in 0·5%
serum and mevastatin with increasing amounts of recombinant PCSK9. LDLR
abundance at the cell surface was determined by flow cytometry.
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